[go: up one dir, main page]

NO20065038L - Anvendelse. - Google Patents

Anvendelse.

Info

Publication number
NO20065038L
NO20065038L NO20065038A NO20065038A NO20065038L NO 20065038 L NO20065038 L NO 20065038L NO 20065038 A NO20065038 A NO 20065038A NO 20065038 A NO20065038 A NO 20065038A NO 20065038 L NO20065038 L NO 20065038L
Authority
NO
Norway
Prior art keywords
compound
isomer
energy balance
negative energy
ruminants
Prior art date
Application number
NO20065038A
Other languages
English (en)
Inventor
Jr Marcus Eugene Kehrli
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20065038L publication Critical patent/NO20065038L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det beskrives anvendelse av en forbindelse av formel (I): en isomer derav, et prodrug av nevnte forbindelse eller isomer, eller et farmasøytisk akseptabelt salt av nevnte forbindelse, isomer eller prodrug, for fremstilling av et medikament for lindrende, profylaktisk eller helbredende virkning på negativ energibalanse i drøvtyggere. Anvendelse av en forbindelse av formel (I) for fremstilling av et medikament for lindrende, profylaktisk eller helbredende behandling av drøv-tyggersykdom assosiert med negativ energibalanse i drøvtyggere, hvor drøvtyggersykdommen assosiert med negativ energibalanse er valgt blant fettleversyndrom, dystocia, immundysfunksjon, svekket immunfunksjon, toksifisering, primær ketose, sekundær ketose, downer kusyndrom, dårlig fordøyelighet, manglende appetitt, svekket placenta, forskjøvet løypemage, mastitt, (endo-)-metritis, infertilitet, lav fertilitet og uførhet. (I) Hvor V, Y, F, G, A, W, E, X, m og n er som definert i krav 1.
NO20065038A 2004-05-25 2006-11-02 Anvendelse. NO20065038L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57417104P 2004-05-25 2004-05-25
PCT/IB2005/001438 WO2005115389A2 (en) 2004-05-25 2005-05-13 Specific ppar agonists for treating negative energy balance

Publications (1)

Publication Number Publication Date
NO20065038L true NO20065038L (no) 2006-12-01

Family

ID=34967765

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065038A NO20065038L (no) 2004-05-25 2006-11-02 Anvendelse.

Country Status (15)

Country Link
US (1) US20070281935A1 (no)
EP (1) EP1753426A2 (no)
JP (1) JP2008500323A (no)
CN (1) CN1956719A (no)
AR (1) AR049185A1 (no)
AU (1) AU2005247164B2 (no)
BR (1) BRPI0511481A (no)
CA (1) CA2567398A1 (no)
IL (1) IL179244A0 (no)
MX (1) MXPA06013754A (no)
NO (1) NO20065038L (no)
RU (1) RU2353362C2 (no)
TW (1) TWI280879B (no)
WO (1) WO2005115389A2 (no)
ZA (1) ZA200609235B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0511613A (pt) * 2004-05-25 2008-01-02 Pfizer Prod Inc uso de agonista de ppar
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
US8133901B2 (en) * 2006-12-01 2012-03-13 Actelion Pharmaceuticals Ltd. 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors
GB0722769D0 (en) * 2007-11-21 2008-01-02 Biolipox Ab New compounds
JP2010521444A (ja) * 2007-03-12 2010-06-24 バイオリポックス エービー 炎症の治療において有用なピペリジノン類
CA2745643C (en) * 2008-12-02 2015-12-01 Danisco A/S A bacillus pumilus strain and methods for improving ruminant health and performance
DE102009038123A1 (de) 2009-08-17 2011-02-24 Aicuris Gmbh & Co. Kg Substituierte (Thiazolyl-carbonyl)imidazolidinone und ihre Verwendung
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
CN116162056A (zh) * 2021-11-24 2023-05-26 上海医药工业研究院 β-catenin/BCL9蛋白-蛋白相互作用的小分子抑制剂及其应用
WO2024145931A1 (zh) * 2023-01-06 2024-07-11 上海医药工业研究院有限公司 β-catenin/BCL9蛋白蛋白相互作用的小分子抑制剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340734A1 (fr) * 1976-02-13 1977-09-09 Roussel Uclaf Nouveaux derives de la m-trifluoromethylphenyl piperidine et leurs sels, procede de preparation et application a titre de medicaments
US5854211A (en) * 1993-12-23 1998-12-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
DE10238865A1 (de) * 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CN100439337C (zh) * 2002-11-26 2008-12-03 辉瑞产品公司 作为ppar活化剂的苯基取代的哌啶化合物
GEP20084393B (en) * 2003-04-24 2008-06-10 Incyte Corp Aza spiro alkane derivatives as inhibitors of metalloproteases
BRPI0511613A (pt) * 2004-05-25 2008-01-02 Pfizer Prod Inc uso de agonista de ppar

Also Published As

Publication number Publication date
IL179244A0 (en) 2007-03-08
WO2005115389A2 (en) 2005-12-08
CA2567398A1 (en) 2005-12-08
AU2005247164B2 (en) 2008-11-27
RU2006141628A (ru) 2008-05-27
ZA200609235B (en) 2008-08-27
AU2005247164A1 (en) 2005-12-08
MXPA06013754A (es) 2007-02-08
EP1753426A2 (en) 2007-02-21
RU2353362C2 (ru) 2009-04-27
JP2008500323A (ja) 2008-01-10
WO2005115389A3 (en) 2006-11-16
AR049185A1 (es) 2006-07-05
CN1956719A (zh) 2007-05-02
BRPI0511481A (pt) 2007-12-26
TWI280879B (en) 2007-05-11
US20070281935A1 (en) 2007-12-06
TW200607501A (en) 2006-03-01

Similar Documents

Publication Publication Date Title
NO20065038L (no) Anvendelse.
ES2186787T3 (es) Utilizacion de ritonavir (abt-538) para mejorar la farmacocinetica de medicamentos metabolizados por el citocromo p450 en un metodo de tratamiento del sida.
CR9842A (es) Composiciones de celecoxib
WO2004066910A3 (en) Controlled release modifying complex and pharmaceutical compositions thereof
NO20040511L (no) Aminoisoxazolderivater som kinaseinhibitorer
NO20035139D0 (no) Karbocykliske hydrazininhibitorer for kobber inneholdende aminoksydaser
US20230233506A1 (en) Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker
CA2541813A1 (en) Methods for treating acute and overuse sprain and strain using hyaluronic acid
JP2006503095A (ja) 反応性関節炎または滑液包炎の治療法
BR0312123A (pt) Agentes de gnrh não peptìdicos, composições farmacêuticas e métodos para o seu uso
WO2004039822A3 (en) 4’’ - modified erythromycin derivatives
RU2008102249A (ru) Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания
WO2022023533A3 (en) Antiviral use of liraglutide and gefitinib
WO2004037166A3 (en) Therapeutic guanidines
DK0561882T3 (da) Hydroxamsyrederivater, som inhiberer lipoxygenase
WO2023152682A9 (en) Contraceptive methods with scheduled bleeding effects
WO2003051301A3 (en) USE OF dsRNAs IN STRATEGIC THERAPEUTIC INTERVENTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
AR051674A1 (es) Farmacos y profarmacos utiles para el tratamiento de equilibrio energetico en rumiantes
CN113677682A (zh) 作为XIa因子抑制剂的大环衍生物
DK1818052T3 (da) Anvendelse af formoterol i den profylaktiske og/eller terapeutiske behandling af muskelsvind og/eller kakektisk syndrom i forbindelse med kataboliske forhold af visse sygdomme såsom cancer, aids, infektioner, diabetes og andre
RU2006107649A (ru) Производные 2-алкилиден-19-нор-витамина d для лечения слабости, поражения мышц или саркопении
RU2004132290A (ru) Способ лечения острого иксодового клещевого боррелиоза на фоне хронического описторхоза
CO2024000737A2 (es) Anticoncepción oral con progestágeno solo
RU2007125264A (ru) Способ лечения повреждений слизистой оболочки желудочно-кишечного тракта
BRPI0406580A (pt) Uso de carbamato de (s)-n-etil-n-metil-3-[1-(dimetilamino)etil]-fenil, uso de um ou mais ingredientes ativos e medicamento para a profilaxia de envenenamento por inibidores de colinesterase

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application